Acute respiratory distress syndrome(ARDS)is characterized by the severe inflammation and destruction of the lung aireblood barrier,leading to irreversible and substantial respiratory function damage.Patients with coro...Acute respiratory distress syndrome(ARDS)is characterized by the severe inflammation and destruction of the lung aireblood barrier,leading to irreversible and substantial respiratory function damage.Patients with coronavirus disease 2019(COVID-19)have been encountered with a high risk of ARDS,underscoring the urgency for exploiting effective therapy.However,proper medications for ARDS are still lacking due to poor pharmacokinetics,non-specific side effects,inability to surmount pulmonary barrier,and inadequate management of heterogeneity.The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery.Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy,which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment.Through passive,active,or physicochemical targeting,nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment,thereby showing good therapeutic activity and reduced toxicity.This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy,highlights the strategies for targeted treatment of lung inflammation,presents the innovative drug delivery systems,and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.展开更多
To study the physiopathologic basis of Weikangfu Granule （胃康复冲剂, WKFG） in treating precancerosis of gastric mucosa in patients of chronic gastritis with Pi-deficiency syndrome （CGPDS）. Methods： One hundred a...To study the physiopathologic basis of Weikangfu Granule （胃康复冲剂, WKFG） in treating precancerosis of gastric mucosa in patients of chronic gastritis with Pi-deficiency syndrome （CGPDS）. Methods： One hundred and fifteen patients of CG-PDS who suffered from intestinal metaplasia （IM） and atypical hyperplasia （ATHP） of gastric mucosa, were divided into two groups. The treated group （n=61） was treated by WKFG with its ingredients modified according to the syndrome type of patients. The control group（n=54） was treated with Weishu granule （胃舒冲剂）. The histopathological and subcellular ultrastructural changes were detected by optical microscope, screening electronic microscope, transmission electronic microscope and histochemical staining; the nuclear and mitochondrial ultrastructure of gastric mucosa were analyzed with energy dispersion X-ray analyser and image analysis system. And the changes of cAMP, lipid peroxide （LPO）, superoxide dismutase （SOD） before and after treatment in the treated group were measured and compared with those of the health control group consisting of 15 volunteers. Results： The symptomatic and pathological therapeutic effect in the treated group were significantly superior to those in the control group （P〈0.05）. The contents of Zn, Cu, cAMP, SOD and 3H-TdR LCT in gastric mucosa of the treated group before treatment were all lower than those of the healthy control group, yet all these indexes markedly increased after treatment, while serum LPO level, which increased before treatment was lowered after treatment. All the changes showed statistical significance （P〈0.05 or P〈0.01）. Conclusion： WKFG can reverse IM and ATHP in patients of CG-PDS, and the effect may be realized by way of increasing the level of Zn, Cu, cAMP and SOD in gastric mucosa, promoting cell differentiation, enhancing cellular immunity and reducing oxygen free radicals and lipid peroxidation.展开更多
基金supported by the National Natural Science Foundation of China(81872810)Program for HUST Academic Frontier Youth Team(2018QYTD13,China)the Fundamental Research Funds for the Central Universities(2018KFYYXJJ019 and 2019KFYRCPY049,China)。
文摘Acute respiratory distress syndrome(ARDS)is characterized by the severe inflammation and destruction of the lung aireblood barrier,leading to irreversible and substantial respiratory function damage.Patients with coronavirus disease 2019(COVID-19)have been encountered with a high risk of ARDS,underscoring the urgency for exploiting effective therapy.However,proper medications for ARDS are still lacking due to poor pharmacokinetics,non-specific side effects,inability to surmount pulmonary barrier,and inadequate management of heterogeneity.The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery.Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy,which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment.Through passive,active,or physicochemical targeting,nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment,thereby showing good therapeutic activity and reduced toxicity.This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy,highlights the strategies for targeted treatment of lung inflammation,presents the innovative drug delivery systems,and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.
文摘To study the physiopathologic basis of Weikangfu Granule （胃康复冲剂, WKFG） in treating precancerosis of gastric mucosa in patients of chronic gastritis with Pi-deficiency syndrome （CGPDS）. Methods： One hundred and fifteen patients of CG-PDS who suffered from intestinal metaplasia （IM） and atypical hyperplasia （ATHP） of gastric mucosa, were divided into two groups. The treated group （n=61） was treated by WKFG with its ingredients modified according to the syndrome type of patients. The control group（n=54） was treated with Weishu granule （胃舒冲剂）. The histopathological and subcellular ultrastructural changes were detected by optical microscope, screening electronic microscope, transmission electronic microscope and histochemical staining; the nuclear and mitochondrial ultrastructure of gastric mucosa were analyzed with energy dispersion X-ray analyser and image analysis system. And the changes of cAMP, lipid peroxide （LPO）, superoxide dismutase （SOD） before and after treatment in the treated group were measured and compared with those of the health control group consisting of 15 volunteers. Results： The symptomatic and pathological therapeutic effect in the treated group were significantly superior to those in the control group （P〈0.05）. The contents of Zn, Cu, cAMP, SOD and 3H-TdR LCT in gastric mucosa of the treated group before treatment were all lower than those of the healthy control group, yet all these indexes markedly increased after treatment, while serum LPO level, which increased before treatment was lowered after treatment. All the changes showed statistical significance （P〈0.05 or P〈0.01）. Conclusion： WKFG can reverse IM and ATHP in patients of CG-PDS, and the effect may be realized by way of increasing the level of Zn, Cu, cAMP and SOD in gastric mucosa, promoting cell differentiation, enhancing cellular immunity and reducing oxygen free radicals and lipid peroxidation.
